Searchable abstracts of presentations at key conferences in endocrinology

ea0015p91 | Clinical practice/governance and case reports | SFEBES2008

Growth hormone replacement in patients with treated germ cell tumours: safety issues

Chung Teng-Teng LL , Kelly Phillip , Metcalfe Karl , Akker Scott , Drake William , Monson John

The potential for primary tumour relapse is an important consideration during GH replacement therapy (GHR). We report 3 cases of relapse of intra cranial germ cell tumour (GCT) during GHR.Patient 1: An 11 year-old female presenting with visual loss and short stature due to a suprasellar malignant teratoma. She was successfully treated with bleomycin, etoposide and cisplatinum (BEP) and intrathecal chemotherapy. She suffered a first relapse two years late...